Full Year 2024 Integral Diagnostics Ltd Earnings Call Transcript
Key Points
- Integral Diagnostics Ltd (ASX:IDX) achieved a 6.6% increase in revenue to $469.7 million.
- Operating EBITDA grew by 7.4% to $91.5 million, with an improved EBITDA margin of 19.5%.
- The company declared a fully franked final dividend of $0.033 per share.
- IDX reduced its leverage by 0.3 times to 2.6 times, showing improved financial stability.
- The proposed merger with Capitol Health Limited is expected to bring significant benefits and synergies.
- Statutory net profit after tax showed a loss of $60.7 million due to impairment in New Zealand.
- High labor costs driven by inflation and labor market supply constraints impacted margins.
- The company faced prolonged cost pressures, particularly in the first six months of FY24.
- IDX experienced a decline in volume by 0.5%, attributed to patients seeking bulk billing alternatives.
- The company had to undertake a restructure in late 2023 due to cost inflation and pressures.
Thank you for standing by, and welcome to the Integral Diagnostics IDX FY24 results conference call. (Operator instructions)
I would now like to hand the conference over to Dr. Ian Kadish, CEO. Thank you. Please go ahead.
Thank you very much, Jody, and good morning, everybody, who's called in this morning. My name is Ian Kadish. I'm the Managing Director and Chief Executive Officer of Integral Diagnostics. I'm joined here this morning by Craig White. Craig is our Chief Financial Officer. We're privileged to be discussing with you this morning the financial year 2024 results for Integral Diagnostics.
We're proud that we delivered on our values in financial year '24, we delivered excellent patient net promoter scores of plus 84 in Australia and plus 86 in New Zealand. We serve more than a million patients. this year and performed more than 2.5 million exams. We also invested nearly $24 million in CapEx, including investment in new and upgraded
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
